ArticleMolecular microbiology2010
Control of effector export by the Pseudomonas aeruginosa type III secretion proteins PcrG and PcrV.
Article in Molecular microbiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed.
- L2 β-lactamase contributes to ceftolozane-tazobactam resistance inAntimicrobial agents and chemotherapy · 2026Article
- Article
- Type III secretion system chaperones: a helping hand for secretion.Microbiology (Reading, England) · 2026Review
- A novel mechanism of ceftolozane-tazobactam resistance inbioRxiv : the preprint server for biology · 2026Article
- Neutralizing human monoclonal antibodies that target the PcrV component of the type III secretion system ofeLife · 2026Article
- The small non-coding RNA sRNA102 regulatesFrontiers in cellular and infection microbiology · 2026Article
- A biofilm-tropiceLife · 2025Article
- Article
- Article
- A whole-cell platform for discovering synthetic cell adhesion molecules in bacteria.Nature communications · 2024Article
- Virulence-associated type III secretion systems in Gram-negative bacteria.Microbiology (Reading, England) · 2023Review
- Self-assembled ferritin nanoparticles displaying PcrV and OprI as an adjuvant-freeFrontiers in immunology · 2023Article
- Functional and Structural Characterization of OXA-935, a Novel OXA-10-Family β-Lactamase from Pseudomonas aeruginosa.Antimicrobial agents and chemotherapy · 2022Article
- Heterologous Assembly of the Type VI Secretion System Empowers Laboratory Escherichia coli with Antimicrobial and Cell Penetration Capabilities.Applied and environmental microbiology · 2022Article
- Genome-wide protein-DNA interaction site mapping in bacteria using a double-stranded DNA-specific cytosine deaminase.Nature microbiology · 2022Article
- A Standardized Extract ofFrontiers in microbiology · 2022Article
- RecombinantInfection and immunity · 2021Article
- Cell-type-specific hypertranslocation of effectors by the Pseudomonas aeruginosa type III secretion system.Molecular microbiology · 2021Article
- Why? - Successful Pseudomonas aeruginosa clones with a focus on clone C.FEMS microbiology reviews · 2020Review
- Construction and Loss of Bacterial Flagellar Filaments.Biomolecules · 2020Review
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
Pseudomonas aeruginosa uses a type III secretion system to inject protein effectors into a targeted host cell. Effector secretion is triggered by host cell contact. How effector secretion is prevented prior to cell contact is not well understood. In all secretion systems studied to date, the needle tip protein is required for controlling effector secretion, but the mechanism by which needle tip proteins control effector secretion is unclear. Here we present data that the P. aeruginosa needle tip protein, PcrV, controls effector secretion by assembling into a functional needle tip complex. PcrV likely does not simply obstruct the secretion channel because the pore-forming translocator proteins can still be secreted while effector secretion is repressed. This finding suggests that PcrV controls effector secretion by affecting the conformation of the apparatus, shifting it from the default, effector secretion 'on' conformation, to the effector secretion 'off' conformation. We also present evidence that PcrG, which can bind to PcrV and is also involved in controlling effector export, is cytoplasmic and that the interaction between PcrG and PcrV is not required for effector secretion control by either protein. Taken together, these data allow us to propose a working model for control of effector secretion by PcrG and PcrV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.